Overview

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
A new drug called azeliragon could be used to treat patients with COVID-19 but the researchers don't know. In this study, they are learning the effects of azeliragonon patients hospitalized for COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Salim S. Hayek